Table 3.

Anti-PD1 Therapies for Advanced cSCC

Study	Regimen	Line of Therapy	Pts (n)	Response Rate	Duration of Response	Notes/Limitations
Migden MR et al. 2018 [50]	Cemiplimab	First Line (31%) Second+ Line (69%)	26	CR 0% PR 50% ORR 50%	Median NR	Expansion Cohorts of Phase I Study including Locally Advanced or Metastatic cSCC
Migden MR et al. 2020[52]	Cemiplimab	First and Second+ Line	78	CR 13% PR 31% ORR 44%	Median NR KM DOR 89%	Phase II Locally advanced cSCC Cohort KM 1 year OS 81% KM 1 year PFS 53%
Richscin D et al. 2020[51]	Cemiplimab	First and Second+ Line	71	CR 11% PR 34% ORR 45%	Median NR KM DOR 90%	DCR 68% KM 1 year OS 81% KM 1 year PFS 51.2%
In GK et al. 2020[84]	Cemiplimab (13) Pembrolizumab (7) Nivolumab (6)	First and second+ Line	26	CR 23% PR 19% ORR 42%	Median 7.6 months	Retrospective study Median PFS 5.4 months
Maubec E et al. 2020[54]	Pembrolizumab	First Line (31%) Second+ Line (69%)	57	CR 8% PR 33% ORR 41%	Median NR	DCR 60%
Salzmann M et al. 2020[85]	Cemiplimab (8) Pembrolizumab (28) Nivolumab (10)	First Line (67%) Second+ Line (33%)	46	CR 15% PR 44% ORR 59%	-	Retrospective study DCR 80% KM 1 year PFS 59%
Grob JJ et al. 2020[53]	Pembrolizumab	First Line (13%) Second+ Line (87%)	105	CR 4% PR 31% ORR 34%	Median NR	DCR 52.4% Median PFS 6.9 months Median OS NR
Eton O et al. 2020[86]	Pembrolizumab + panitumumab (1) Nivolumab + panitumumab (1)	Second+ Line	2	CR 100% ORR 100%		Case series

Note this table is just a limited sampling of published reports including PD-1 inhibitor therapies for advanced cutaneous SCC.

CR= complete response; PR = partial response; ORR = overall response rate; ST = surgical therapy; RT = radiation therapy; Pts = patients; DCR = Disease Control Rate; DOR= Duration of Response; cSCC = Cutaneous Squamous Cell Carcinoma; NR= Not Reached; KR = Kaplan-Meier estimate 12-month estimate